Brokerages Set ZEALAND PHARMA/S (ZEAL) Price Target at $24.00

ZEALAND PHARMA/S (NASDAQ:ZEAL) has received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $24.00.

A number of research analysts recently issued reports on ZEAL shares. Needham & Company LLC lifted their price target on shares of ZEALAND PHARMA/S from $26.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, September 19th. ValuEngine raised shares of ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a research report on Friday. Zacks Investment Research raised shares of ZEALAND PHARMA/S from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Tuesday, January 1st. Goldman Sachs Group cut shares of ZEALAND PHARMA/S from a “buy” rating to a “neutral” rating in a research report on Monday, December 17th. Finally, reaffirmed a “positive” rating on shares of ZEALAND PHARMA/S in a report on Thursday, September 27th.

NASDAQ ZEAL opened at $14.25 on Friday. The company has a market capitalization of $435.65 million, a price-to-earnings ratio of -9.63 and a beta of 1.90. ZEALAND PHARMA/S has a 1 year low of $11.51 and a 1 year high of $18.91.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last posted its quarterly earnings data on Thursday, November 15th. The company reported $4.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $5.20. ZEALAND PHARMA/S had a negative net margin of 483.00% and a positive return on equity of 91.98%. As a group, equities analysts anticipate that ZEALAND PHARMA/S will post -2.47 earnings per share for the current fiscal year.

ZEALAND PHARMA/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Read More: What Factors Can Affect Return on Equity?

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply